In their study, published in the journal Proceedings of the National Academy of Sciences, prostate cancer growth in mice with functioning immune systems was inhibited by sensitizing the cancer cells with the drug Sabutoclax (BI-97C1) and using UTMD technology to deliver a viral gene therapy that expresses the genemda-7/IL-24. This powerful new approach to treating prostate cancer builds upon prior studies by principle investigator Paul B. Fisher, M.P.H., Ph.D., Thelma Newmeyer Corman Endowed Chair in Oncology Research at VCU Massey (photo on left). Fisher is professor and chair of the Department of Human and Molecular Genetics in the VCU School of Medicine, and director of the VCU Institute of Molecular Medicine.
Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma. Currently, there is virtually no effective treatment for HCC, and this breakthrough identifies a promising new target for therapeutic intervention.
Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal Blood, are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.
Nationally recognized expert on decision-making in organ and tissue donation Laura Siminoff, Ph.D., received a $283,000 grant from the National Institutes of Health to support her contribution to the NIHs newly launched Genotype-Tissue Expression Project. The Genotype-Tissue Expression Project is designed to understand how genetic variation may control gene activity and its relationship to disease. It will generate data about how gene expression is regulated in different organs in the human body, which will then serve as a resource for researchers across the country to study inherited susceptibility to illness and establish a tissue bank for biological studies down the road.
Adhering to cancer screening recommendations is one of the best things people can do to reduce their risk of dying from cancer. But research at Virginia Commonwealth University Massey Cancer Center suggests that when patients are presented more than one colorectal cancer screening option, there is a greater chance of confusion and, therefore, a greater chance of neglecting screening recommendations.